Glucose dysregulation in pre-clinical Alzheimer's disease.
journal contributionposted on 19.01.2021, 12:01 by Niamh Connolly, Pierre Theurey, Paola Pizzo
AD is the most common cause of age-related dementia and is consistently accompanied by glucose hypo-metabolism that precedes the onset of clinical symptoms, providing potential for early diagnosis and novel therapeutic interventions. Innovative inter-disciplinary research utilising appropriate pre-clinical models is required to further elucidate the molecular mechanisms, cross-talk with Aβ and tau pathology, and translatable approaches targeted to the early stages of AD. Given that glucose hypo‑metabolism has also been measured in other neurodegenerative diseases, we are excited to watch this field progress.
CeBioND EU Joint Programme for Neurodegenerative Disease Research
CommentsThe original article is available at https://www.aging-us.com/
Published CitationConnolly NMC, Theurey P, Pizzo P. Glucose dysregulation in pre-clinical Alzheimer's disease. Aging (Albany NY). 2019;11(15):5296-5297.
Publication Date4 August 2019
- Centre for Systems Medicine
- Physiology and Medical Physics
- Neurological and Psychiatric Disorders
PublisherImpact Journals, LLC
- Published Version (Version of Record)